NRG/RTOG 0837: Randomized, phase II, double-blind, placebo-controlled trial of chemoradiation with or without cediranib in newly diagnosed glioblastoma Article

Batchelor, Tracy T, Won, Minhee, Chakravarti, Arnab et al. NRG/RTOG 0837: Randomized, phase II, double-blind, placebo-controlled trial of chemoradiation with or without cediranib in newly diagnosed glioblastoma . 5(1),

cited authors

  • Batchelor, Tracy T; Won, Minhee; Chakravarti, Arnab; Hadjipanayis, Costas G; Shi, Wenyin; Ashby, Lynn S; Stieber, Volker W; Robins, H Ian; Gray, Heidi J; Voloschin, Alfredo; Fiveash, John B; Robinson, Clifford G; Chamarthy, UshaSree; Kwok, Young; Cescon, Terrence P; Sharma, Anand K; Chaudhary, Rekha; Polley, Mei-Yin; Mehta, Minesh P

authors

keywords

  • BEVACIZUMAB
  • CRITERIA
  • Clinical Neurology
  • ENDOTHELIAL GROWTH-FACTOR
  • GLIOMAS
  • LOMUSTINE
  • Life Sciences & Biomedicine
  • Neurosciences & Neurology
  • Oncology
  • REGRESSION
  • Science & Technology
  • TEMOZOLOMIDE
  • angiogenesis | cediranib | glioblastoma | vascular endothelial
  • growth factor

publisher

  • OXFORD UNIV PRESS

volume

  • 5

issue

  • 1